Therapeutic targets in subependymoma

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 168-175

  Kong, Ling Yuan ^a   Wei, Jun ^a   Haider, Ali S ^a   Liebelt, Brandon D ^b   Ling, Xiaoyang ^a   Conrad, Charles A ^a   Fuller, Gregory N ^a   Levine, Nicholas B ^a   Priebe, Waldemar ^a   Sawaya, Raymond ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Houston Methodist ^*  (United States)

Author keywords

Ependymoma; Immunotherapy; Noninvasive; Subependymoma

Indexed keywords

BERUBICIN; CHEMOKINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 13 RECEPTOR ALPHA2; ISOCITRATE DEHYDROGENASE 1; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 2; STAT3 PROTEIN; TOPOISOMERASE II BETA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; WP 1066; WP 1193; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; TUMOR PROTEIN; TYRPHOSTIN;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPENDYMOMA; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; IMMUNOCOMPETENT CELL; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUBEPENDYMOMA; TUMOR MICROENVIRONMENT; BRAIN TUMOR; CANCER STEM CELL; CFU COUNTING; CHEMISTRY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; EMBRYOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA, SUBEPENDYMAL; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PYRIDINES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS; TYRPHOSTINS;

EID: 84919402307     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.10.008     Document Type: Article

References (37)

1. Abou-Ghazal M., Yang D.S., Qiao W., Reina-Ortiz C., Wei J., Kong L.Y., et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin. Cancer Res. 2008, 14:8228-8235.
2. Brooks T.A., O'Loughlin K.L., Minderman H., Bundy B.N., Ford L.A., Vredenburg M.R., et al. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest. New Drugs 2007, 25:115-122.
3. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
4. Conrad C., Koul D., Guan S., Fokt I., Shen R., Ramnarian D., et al. Berubicin: a novel topoisomerase II inhibitor with activity in ependymoma 2009, Society of Neuro-Oncology, New Orleans, LA.
5. Doucette T.A., Kong L.Y., Yang Y., Ferguson S.D., Yang J., Wei J., et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro-Oncol. 2012, 14(9):1136-1145.
6. Erfani N., Razmkhah M., Ghaderi A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Investig. 2010, 28:828-832.
7. Faderl S., Estrov Z., Kantarjian H.M., Harris D., Van Q., Fokt I., et al. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001, 21:3777-3784.
8. Fecci P.E., Ochiai H., Mitchell D.A., Grossi P.M., Sweeney A.E., Archer G.E., et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 2007, 13:2158-2167.
9. Ferrajoli A., Faderl S., Van Q., Koch P., Harris D., Liu Z., et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007, 67:11291-11299.
10. Ge L., Hoa N., Bota D.A., Natividad J., Howat A., Jadus M.R. Immunotherapy of brain cancers: the past, the present, and future directions. Clin. Dev. Immunol. 2010, 2010:19. (Article ID 296453).
11. Heimberger A.B., Hlatky R., Suki D., Yang D., Weinberg J., Gilbert M., et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 2005, 11:1462-1466.
12. Hermanson M., Funa K., Hartman M., Claesson-Welsh L., Heldin C.H., Westermark B., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992, 52:3213-3219.
13. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
14. Hussain S.F., Kong L.Y., Jordan J., Conrad C., Madden T., Fokt I., et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007, 67:9630-9636.
15. Inge T.H., Harris N.L., Wu J., Azizkhan R.G., Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J. Surg. Res. 2004, 121:187-196.
16. Jooma R., Torrens M.J., Bradshaw J., Brownell B. Subependymomas of the fourth ventricle. Surgical treatment in 12 cases. J. Neurosurg. 1985, 62:508-512.
17. Kadota M., Yang H.H., Gomez B., Sato M., Clifford R.J., Meerzaman D., et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 2010, 5:e9201.
18. Kanwar J.R., Roy K., Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 2011, 46:459-477.
19. Kong L.Y., Abou-Ghazal M.K., Wei J., Chakraborty A., Sun W., Qiao W., et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin. Cancer Res. 2008, 14:5759-5768.
20. Kong L.Y., Wei J., Sharma A.K., Barr J., Abou-Ghazal M.K., Fokt I., et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol. Immunother. 2009, 58:1023-1032.
21. Li A., Walling J., Kotliarov Y., Center A., Steed M.E., Ahn S.J., et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 2008, 6:21-30.
22. Lombardi D., Scheithauer B.W., Meyer F.B., Forbes G.S., Shaw E.G., Gibney D.J., et al. Symptomatic subependymoma: a clinicopathological and flow cytometric study. J. Neurosurg. 1991, 75:583-588.
23. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W. World Health Organization classification of tumours. WHO Classification of Tumours of the Central Nervous System 2007, 70-71. International Agency for Research on Cancer (IARC), Lyon, France. 4th ed. F.T. Bosman, E.S. Jaffe, S.R. Lakhani, H. Ohgaki (Eds.).
24. Mitchell D.A., Archer G., Bigner D., Friedman A.H., Friedman H.S., Reardon D., et al. RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma. Neuro-Oncol. 2007, 9:509.
25. Nilsson C.L., Dillon R., Devakumar A., Shi S.D., Greig M., Rogers J.C., et al. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J. Proteome Res. 2010, 9:430-443.
26. Okada H., Low K.L., Kohanbash G., McDonald H.A., Hamilton R.L., Pollack I.F. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J. Neurooncol. 2008, 88:245-250.
27. Penafuerte C., Bautista-Lopez N., Bouchentouf M., Birman E., Forner K., Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J. Immunol. 2011, 186:6933-6944.
28. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:4722-4729.
29. Sampson J.H., Aldape K.D., Archer G.E., Coan A., Desjardins A., Friedman A.H., et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncol. 2011, 13:324-333.
30. Scheithauer B.W. Symptomatic subependymoma. Report of 21 cases with review of the literature. J. Neurosurg. 1978, 49:689-696.
31. Sironi J.J., Ouchi T. STAT1-induced apoptosis is mediated by caspases 2, 3, and 7. J. Biol. Chem. 2004, 279:4066-4074.
32. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
33. Wainwright D.A., Chang A.L., Dey M., Balyasnikova I.V., Kim C., Tobias A.L., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin. Cancer Res. 2014, 20:5290-5301.
34. Wang H., Zhang W., Fuller G.N. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002, 12:95-107.
35. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 2010, 9:67-78.
36. Wei J., Wu A., Kong L.Y., Wang Y., Fuller G., Fokt I., et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011, 6(1):e16195.
37. Xu Z., Joshi N., Agarwal A., Dahiya S., Bittner P., Smith E., et al. Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. J. Neurooncol. 2012, 108:59-67.